Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06162299
Other study ID # YS-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date May 30, 2024
Est. completion date May 30, 2025

Study information

Verified date November 2023
Source Yisheng Biopharma (Singapore) Pte. Ltd.
Contact Maricris Trillana
Phone +63917 5855628
Email maricris.trillana@yishengbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.


Description:

This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL. Enrollment in the study will sequentially start from the low dose 0.5mL as Group A, then to the mid-dose 1.0mL as Group B and lastly to the high dose of 2.0mL as Group C. Each group will have 16 patients enrolled. The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo (Table 3). As there is no comparable equivalent to YS-HBV-002 available in the market, the placebo of normal saline solution to be injected intramuscularly will serve as the control in this trial. The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo. The vaccination regimen will be 1 IM injection every 3 days in the deltoid muscle, alternately for approximately 6 weeks. A total of 14 injections will be administered to each patient.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date May 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years during screening 2. Body Mass Index (BMI) of 18.5-30 kg/m2 3. Diagnosed or laboratory confirmed to have CHB 1. Have CHB infection for at least 6 months 2. HBsAg titer = 1000 IU/mL 3. HBV DNA = 2000 IU/mL 4. Serum alanine amino transferase (ALT) and aspartate aminotransferase (AST) = 2 × upper limit of normal (ULN) 4. Able to provide informed consent 5. Able and willing to comply with all study procedures throughout the study period of approximately 3 months 6. For female subjects with childbearing potential: must agree to avoid pregnancy throughout the study period of approximately 3 months. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods on avoiding pregnancy include: a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with a spermicide. Exclusion Criteria: 1. Pregnant or breastfeeding or intending to become pregnant within the projected duration of the trial 2. Transient elastography at screening revealing a FibroScan value of = 9 kPa or a previous liver biopsy evidencing hepatic fibrosis at or within 24 months prior to vaccination 3. Patients with hepatitis caused by other etiologies 4. History of or manifestations of liver decompensation (e.g., Child-Pugh Class B or C, or ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, etc....) 5. Currently participating in or has participated in a study with an IP within 30 days preceding Day 0 6. Fever (axillary temperature = 37.8 ?) 7. Subjects with abnormal indicators of blood biochemistry and other routine blood tests deemed clinically significant by the investigator 8. History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema, or allergic abdominal pain) or allergy to any of the components of YS-HBV-002 9. Any history of anaphylaxis or angioedema after any vaccination 10. Allergy to kanamycin and aminoglycosides 11. Past or family history of convulsion, epilepsy, encephalopathy, or mental illness 12. Diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases 13. History of coagulation dysfunction (e.g., coagulation factor deficiency, coagulation disease) 14. Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on the investigator's judgement 15. Vaccinated with live attenuated vaccine within 1 month, or other vaccine/non-COVID-19 vaccine within 14 days prior to vaccination 16. Receiving immunotherapy or inhibitor therapy (consistently oral or infusion for more than 14 days) within 3 months prior to vaccination 17. Received systemic immunosuppressants within 4 months prior to vaccination or anticipating the need for immunosuppressant at any time during participation in the study. Topical or inhaled treatment is allowed if not used within 14 days prior to vaccination 18. Have received antiviral therapy for chronic hepatitis but have stopped for less than 30 days or plan to take antiviral therapy during the study 19. Received blood products within 3 months before vaccine administration 20. History of alcohol or drug abuse within the past 2 years 21. Any condition that, in the opinion of the investigator, would pose a health risk to the patient if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results.

Study Design


Intervention

Biological:
YS-HBV-002
YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yisheng Biopharma (Singapore) Pte. Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AEs within 30 minutes after vaccination. To assess the safety and tolerability 30 minutes post each vaccination
Primary Incidence of solicited local reactions within 7 days after each vaccination. To assess the safety and tolerability 7 days post each vaccination
Primary Incidence of solicited systemic reactions from first vaccination to 7 days after the last vaccination (D1 to D46). To assess the safety and tolerability From Day1 to Day46
Primary Incidence of unsolicited AEs, serious adverse events (SAEs) including suspected unexpected serious adverse reactions (SUSARs), adverse events of special interest (AESIs), and AEs leading to withdrawals throughout the study period To assess the safety and tolerability From Day1 to Day 90
Secondary Proportion of patients showing reduction in HBV DNA using PCR for each dose from baseline to the end of the study and at specified timepoints. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary Change in mean log10 of HBV DNA from baseline to end of study and at each specified timepoint. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study at each specified timepoint. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study and at each specified timepoint. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary Proportion of patients with loss (defined as lower limit of quantitation [LLOQ]) or decline in HBsAg, HBcAg, and HBeAg from baseline to the end of the study and at each specified timepoint. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary GMTs of antibodies against HBsAg, HBcAg and HBeAg at baseline and at pre-defined post-vaccination timepoints. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
Secondary Seroconversion rates of antibodies against HBsAg, HBcAg, and HBeAg. To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose Day0, Day16, Day34, Day60, Day90
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A